SCHEMBL8300316

SCHEMBL8300316

CNCCCCC(C)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11303506 0.97 PAOX (0.57)
SCHEMBL22954504 0.97 PAOX (0.57)
SCHEMBL12118217 0.97 PAOX (0.57)
SCHEMBL18932735 0.97 PAOX (0.57)
SCHEMBL17735332 0.97 PAOX (0.57)
SCHEMBL24812346 0.97 PAOX (0.57)
SCHEMBL805291 0.92
SCHEMBL9925439 0.85 CASP2 (0.50)
SCHEMBL22297129 0.85 PAOX (0.43)
SCHEMBL13292124 0.85 CASP2 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024089405-A2 INSECT NEUROPEPTIDE ANALOGUES Solasta Bio Limited (GB) 2024-05-02 WO disclosed
EP-4289857-A1 DRUG CONJUGATE OF GLUCOCORTICOID RECEPTOR AGONIST, AND APPLICATION THEREOF IN MEDICINE Shanghai Senhui Medicine Co., Ltd. (CN) 2023-12-13 EP disclosed
WO-2022270549-A1 NOVEL POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER 持田製薬株式会社 2022-12-29 WO disclosed
WO-2022145420-A1 NOVEL MULTILAYER POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER 持田製薬株式会社 2022-07-07 WO disclosed
EP-3991792-A1 TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACID Mochida Pharmaceutical Co., Ltd. (JP) 2022-05-04 EP disclosed
WO-2021262731-A2 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-12-30 WO disclosed
WO-2021236695-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR MONTELINO THERAPEUTICS, INC. (US) 2021-11-25 WO disclosed
EP-2275433-B1 METASTIN DERIVATIVE AND USE THEREOF UNIV KYOTO (JP) 2017-06-07 EP disclosed
US-9518152-B2 Polyamide compound and pharmaceutical composition for treating mitochondrial genetic disease Yano, Takamitsu (JP) 2016-12-13 US disclosed
US-20160303062-A1 ANTIMICROBIAL COMPOSITIONS AND METHOD OF USE NATIONAL SCIENCE FOUNDATION 2016-10-20 US disclosed
US-20080305985-A1 Isosteric Transormation APLA-GEN GMBH (DE) 2008-12-11 US disclosed
US-20080200465-A1 Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals GENESOFT PHARMACEUTICALS, INC. (US) 2008-08-21 US disclosed
US-7348427-B2 Antipathogenic benzamide compounds GENESOFT PHARMACEUTICALS, INC. (US) 2008-03-25 US disclosed
US-20080064643-A1 Myd88 Homodimerization Inhibitors SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-03-13 US disclosed
US-7329765-B2 Benzothiophene compounds having antiinfective activity GENESOFT PHARMACEUTICALS, INC. (US) 2008-02-12 US disclosed
US-20070287670-A1 HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-12-13 US disclosed
US-20070287670-A1 HUMAN GLUCAGON-LIKE PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-12-13 US disclosed
US-7238670-B2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-03 US disclosed
US-7238670-B2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-03 US disclosed
WO-2004094461-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-04 WO disclosed